Fucoxanthin induces growth arrest and apoptosis in human bladder cancer T24 cells by up-regulation of p21 and down-regulation of mortalin

Acta Biochimica et Biophysica Sinica

Volumn 46, Issue 10, 2014, Pages 877-884

  Wang, Linbo ^a   Zeng, Yang ^a   Liu, Ye ^a   Hu, Xuansheng ^a   Li, Shuhong ^a   Wang, Yuepeng ^a,b   Li, Ling ^a   Lei, Zhongfang ^a   Zhang, Zhenya ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Natural Product Industry of Tsukuba Co   (Japan)

Author keywords

Fucoxanthin; G0 G1 phase; Human bladder cancer T24 cells; Mortalin; P53

Indexed keywords

FUCOXANTHIN; HEAT SHOCK PROTEIN 70; MORTALIN; PROTEIN P21; XANTHOPHYLL;

APOPTOSIS; BLADDER TUMOR; CELL DIVISION; DOWN REGULATION; DRUG EFFECTS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; DOWN-REGULATION; HSP70 HEAT-SHOCK PROTEINS; HUMANS; PROTO-ONCOGENE PROTEINS P21(RAS); UP-REGULATION; URINARY BLADDER NEOPLASMS; XANTHOPHYLLS;

EID: 84930729174     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmu080     Document Type: Article

References (49)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. Ca-Cancer J Clin 2013, 63:11-30.
2. Kuroda K, Asakuma J, Horiguchi A, Tasaki S, Yoshii H, Sato A and Ito K, et al. Prognostic factors for upper urinary tract urothelial carcinoma after nephroureterectomy. Urol Int 2012, 88:225-231.
3. Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS and Novara G, et al. Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol 2011, 8:440-447.
4. Comperat E, Roupret M, Chartier-Kastler E, Bitker MO, Richard F, Camparo P and Capron F, et al. Prognostic value of MET, RON and histoprognostic factors for urothelial carcinoma in the upper urinary tract. J Urol 2008, 179:868-872.
5. Kobayashi S, Fujii Y, Koga F, Yokoyama M, Ishioka J, Matsuoka Y and Numao N, et al. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study. Urol Oncol 2014, 32:29-36.
6. Bruins HM, Skinner EC, Dorin RP, Ahmadi H, Djaladat H, Miranda G and Cai J, et al. Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: results from a prospective lymph node mapping study. Urol Oncol 2014, 32:13-29.
7. van Lingen AV and Witjes JA. Current intravesical therapy for non-muscle invasive bladder cancer. Expert Opin Biol Th 2013, 13:1371-1385.
8. Turker P and Turkeri L. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer. Arch Espan Urol 2013, 66:833-840.
9. Singer S, Ziegler C, Schwalenberg T, Hinz A, Gotze H and Schulte T. Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Support Care Cancer 2013, 21:1383-1393.
10. Sasaki Y, Oi H, Oyama T, Kagawa J, Komori M, Senzaki T and Fukawa T, et al. Non-muscle invasive bladder cancer with multiple bone metastasis without local invasion: a case report. Acta Urol Jpn 2013, 59:669-672.
11. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A and Keogh JP, et al. Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial. J Natl Cancer Inst 1996, 88:1550-1559.
12. Kotake-Nara E, Asai A and Nagao A. Neoxanthin and fucoxanthin induce apoptosis in PC-3 human prostate cancer cells. Cancer Lett 2005, 220:75-84.
13. Hosokawa M, Kudo M, Maeda H, Kohno H, Tanaka T and Miyashita K. Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARgamma ligand, troglitazone, on colon cancer cells. Biochim Biophys Acta 2004, 1675:113-119.
14. Kim KN, Heo SJ, Kang SM, Ahn G and Jeon YJ. Fucoxanthin induces apoptosis in human leukemia HL-60 cells through a ROS-mediated Bcl-xL pathway. Toxicol In Vitro 2010, 24:1648-1654.
15. Liu CL, Lim YP and Hu ML. Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174 T cells. Mar. Drugs 2012, 10:242-257.
16. Satomi Y. Fucoxanthin induces GADD45A expression and G1 arrest with SAPK/JNK activation in LNCap human prostate cancer cells. Anticancer Res 2012, 32:807-813.
17. Xiao X, Si X, Yuan Z, Xu X and Li G. Isolation of fucoxanthin from edible brown algae by microwave-assisted extraction coupled with high-speed countercurrent chromatography. J Sep. Sci 2012, 35:2313-2317.
18. Zhang Z, Zhang P, Hamada M, Takahashi S, Xing G, Liu J and Sugiura N. Potential chemoprevention effect of dietary fucoxanthin on urinary bladder cancer EJ-1 cell line. Oncol Rep 2008, 20:1099-1103.
19. O'Toole CM PS, Hepburn P and Franks LM. Identity of some human bladder cancer cell lines. Nature 1983, 5899:429-430.
20. Lane DP. Cancer - P53, Guardian of the Genome. Nature 1992, 358:15-16.
21. Hainaut P and Hollstein M. p53 and human cancer: The first ten thousand mutations. Adv Cancer Res 2000, 77:81-137.
22. Donehower LA. Does p53 affect organismal aging? J Cell Physiol 2002, 192:23-33.
23. Marchenko ND, Zaika A and Moll UM. Death signal-induced localization of p53 protein to mitochondria-a potential role in apoptotic signaling. J Biol Chem 2000, 275:16202-16212.
24. Kaul SC, Deocaris CC and Wadhwa R. Three faces of mortalin: a housekeeper, guardian and killer. Exp Gerontol 2007, 42:263-274.
25. Saxena N, Katiyar SP, Liu Y, Grover A, Gao R, Sundar D and Kaul SC, et al. Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization. Biosci Rep 2013, 33:797-806.
26. Wadhwa R, Takano S, Kaur K, Aida S, Yaguchi T, Kaul Z and Hirano T, et al. Identification and characterization of molecular interactions between mortalin/mtHsp70 and HSP60. Biochem J 2005, 391:185-190.
27. Januar HI, Dewi AS, Endar M and Thamrin W. In silico study of fucoxanthin as a tumor cytotoxic agent. J Pharm Bioallied Sci 2012, 4:56-59.
28. Cayrol C and Flemington E. G0/G1 growth arrest mediated by a region encompassing the basic leucine zipper (bZIP) domain of the Epstein-Barr virus transactivator Zta. J Biol Chem 1996, 271:31799-31802.
29. Tanaka T, Knapp D and Nasmyth K. Loading of an Mcm protein onto DNA replication origins is regulated by Cdc6p and CDKs. Cell 1997, 90:649-660.
30. Huppertz B, Frank HG and Kaufmann P. The apoptosis cascade-morphological and immunohistochemical methods for its visualization. Anat Embryol 1999, 200:1-18.
31. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
32. Lu WJ, Lee NP, Kaul SC, Lan F, Poon RT, Wadhwa R and Luk JM. Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death Differ 2011, 18:1046-1056.
33. Lu WJ, Lee NP, Kaul SC, Lan F, Poon RT, Wadhwa R and Luk JM. Induction of mutant p53-dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin. Int J Cancer 2011, 129:1806-1814.
34. Das SK, Hashimoto T, Shimizu K, Yoshida T, Sakai T, Sowa Y and Komoto A, et al. Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1. Biochim Biophys Acta 2005, 1726:328-335.
35. Hou LL, Gao C, Chen L, Hu GQ and Xie SQ. Essential role of autophagy in fucoxanthin-induced cytotoxicity to human epithelial cervical cancer HeLa cells. Acta Pharmacol Sin 2013, 34:1403-1410.
36. Rossi KA, Markwalder JA, Seitz SP, Chang CH, Cox S, Boisclair MD and Brizuela L, et al. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors. J Comput Aid Mol Des 2005, 19:111-122.
37. Liu F. Inhibition of Smad3 activity by cyclin D-CDK4 and cyclin E-CDK2 in breast cancer cells. Cell Cycle 2011, 10:186.
38. Wang CC, Chiang YM, Kuo PL, Chang JK and Hsu YL. Norsolorinic acid inhibits proliferation of T24 human bladder cancer cells by arresting the cell cycle at the G0/G1 phase and inducing a Fas/membrane-bound Fas ligandmediated apoptotic pathway. Clin Exp Pharmacol P 2008, 35:1301-1308.
39. Liu C-L, Huang Y-S, Hosokawa M, Miyashita K and Hu M-L. Inhibition of proliferation of a hepatoma cell line by fucoxanthin in relation to cell cycle arrest and enhanced gap junctional intercellular communication. Chem-Biol Interact 2009, 182:165-172.
40. Mraz M, Malinova K, Kotaskova J, Pavlova S, Tichy B, Malcikova J and Stano Kozubik K, et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 2009, 23:1159-1163.
41. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A and Blandino G. Mutant p53: an oncogenic transcription factor. Oncogene 2007, 26:2212-2219.
42. Ishikawa C, Tafuku S, Kadekaru T, Sawada S, Tomita M, Okudaira T and Nakazato T, et al. Antiadult T-cell leukemia effects of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. Intl J Cancer 2008, 123:2702-2712.
43. Yamamoto K, Ishikawa C, Katano H, Yasumoto T and Mori N. Fucoxanthin and its deacetylated product, fucoxanthinol, induce apoptosis of primary effusion lymphomas. Cancer Lett 2011, 300:225-234.
44. Beppu F, Niwano Y, Tsukui T, Hosokawa M and Miyashita K. Single and repeated oral dose toxicity study of fucoxanthin (FX), a marine carotenoid, in mice. J Toxicol Sci 2009, 34:501-510.
45. Iio K, Okada Y and Ishikura M. Bacterial reverse mutation test and micronucleus test of fucoxanthin oil from microalgae. J Food Hyg Soc Jpn 2011, 52:190-193.
46. Sugawara T, Kushiro M, Zhang H, Nara E, Ono H and Nagao A. Lysophosphatidylcholine enhances carotenoid uptake from mixed micelles by Caco-2 human intestinal cells. J Nutr 2001, 131:2921-2927.
47. Yonekura L, Kobayashi M, Terasaki M and Nagao A. Keto-carotenoids are the major metabolites of dietary lutein and fucoxanthin in mouse tissues. J Nutr 2010, 140:1824-1831.
48. Das SK, Ren R, Hashimoto T and Kanazawa K. Fucoxanthin induces apoptosis in osteoclast-like cells differentiated from RAW264.7 cells. J Agric Food Chem 2010, 58:6090-6095.
49. Sane S, Abdullah A, Boudreau DA, Autenried RK, Gupta BK, Wang X and Wang H, et al. Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells. Cell Death Dis 2014, 5:e1118.